Literature DB >> 10325244

In vivo enzymatic assay reveals catalytic activity of the human renin precursor in tissues.

D Methot1, D W Silversides, T L Reudelhuber.   

Abstract

The aspartyl protease renin is secreted into the circulation of mammals in 2 forms: the proteolytically processed active form of the enzyme and the precursor form, prorenin. Prorenin has no detectable enzymatic activity in the circulation, but it is the exclusive form of the enzyme produced by several tissues that also produce the other components of the renin enzymatic cascade (renin-angiotensin system). To test whether prorenin might be enzymatically active in these tissues, transgenic mice expressing the human renin substrate (angiotensinogen) exclusively in the pituitary gland were mated to mice expressing either active human renin or prorenin in the same tissue. Measurement of in vivo product formation in pituitary glands of double-transgenic mice revealed that human prorenin was enzymatically active, and Western blot analysis demonstrated that this prorenin was in the precursor form with its prosegment attached. This in vivo enzymatic assay demonstrates for the first time that human prorenin can be activated within tissues by nonproteolytic means, where it could contribute to the activity of a localized renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325244     DOI: 10.1161/01.res.84.9.1067

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  A genetically clamped renin transgene for the induction of hypertension.

Authors:  Kathleen M I Caron; Leighton R James; Hyung-Suk Kim; Scott G Morham; Maria Luisa S Sequeira Lopez; R Ariel Gomez; Timothy L Reudelhuber; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

2.  The association of plasma prorenin level with an oxidative stress marker, 8-OHdG, in nondiabetic hemodialysis patients.

Authors:  Yoshiyuki Morishita; Shiho Hanawa; Takuya Miki; Taro Sugase; Yasuhiro Sugaya; Junko Chinda; Osamu Iimura; Sadao Tsunematsu; Kenichi Ishibashi; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-01-15       Impact factor: 2.801

3.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.

Authors:  Genevieve Nguyen; Françoise Delarue; Céline Burcklé; Latifa Bouzhir; Thomas Giller; Jean-Daniel Sraer
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 4.  Renin/prorenin-receptor biochemistry and functional significance.

Authors:  Geneviève Nguyen; Céline A Burcklé; Jean-Daniel Sraer
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

5.  Neuron-specific (pro)renin receptor knockout prevents the development of salt-sensitive hypertension.

Authors:  Wencheng Li; Hua Peng; Eamonn P Mehaffey; Christie D Kimball; Justin L Grobe; Jeanette M G van Gool; Michelle N Sullivan; Scott Earley; A H Jan Danser; Atsuhiro Ichihara; Yumei Feng
Journal:  Hypertension       Date:  2013-11-18       Impact factor: 10.190

6.  Receptor-mediated nonproteolytic activation of prorenin and induction of TGF-β1 and PAI-1 expression in renal mesangial cells.

Authors:  Jiandong Zhang; Jie Wu; Chunyan Gu; Nancy A Noble; Wayne A Border; Yufeng Huang
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-25

7.  Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1-prorenin transgenic rats.

Authors:  Guangyu Zhou; Jie Wu; Chunyan Gu; Bin Wang; E Dale Abel; Alfred K Cheung; Yufeng Huang
Journal:  Clin Sci (Lond)       Date:  2018-06-28       Impact factor: 6.876

8.  Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.

Authors:  Jiandong Zhang; Nancy A Noble; Wayne A Border; Rick T Owens; Yufeng Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 5.900

Review 9.  Brain renin angiotensin in disease.

Authors:  M Ian Phillips; Edilamar Menezes de Oliveira
Journal:  J Mol Med (Berl)       Date:  2008-04-02       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.